A Randomized Control Trial of Narrative Exposure Therapy Versus Treatment as Usual in the Therapy of Borderline Personality Disorder

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01033708

Acronym

NET

Enrollment

Registered

2009-12-16

Start date

2009-10-31

Completion date

2013-10-31

Last updated

2009-12-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Borderline Personality Disorders, Posttraumatic Stress Disorders

Keywords

Psychotherapy, PTSD, Borderline personality disorders

Brief summary

Definition of the efficacy of NET compared with treatment as usual in the treatment of patients with complex traumatic disease (borderline personality disorder (BPD) and posttraumatic stress disorder (PTSD)) as assessed by structured clinical interviews. Furthermore, to evaluate the sleep, cortisol level and epigenetic differences in the process of the specific therapy compared to treatment as usual.

Detailed description

Experimental intervention: Narrative Exposure Therapy (NET), an evidence-based trauma-focussed treatment, suitable for survivors of prolonged and repeated exposure to traumatic stress and childhood adversity. Control intervention: Treatment as usual. Follow-up per patient: 3 follow-up assessments- 4 weeks, 6 months,12 months and 24 months after end of experimental/ control intervention Duration of intervention per patient: Both treatment types will be conducted for 10-14 sessions of 60-90 min in length. Additionally 5 sleep laboratory investigations (1 pre- and 4 post- intervention (4 weeks, 6 months, 12 months, 24 months after treatment)) will be carried out. Additionally the cortisol level in the hair and epigenetic markers will be recorded. The estimated observation time is 2 years.

Interventions

BEHAVIORALnarrative exposure therapy

Narrative Exposure Therapy (NET), an evidence-based trauma-focussed treatment, suitable for survivors of prolonged and repeated exposure to traumatic stress and childhood adversities

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to 45 Years

Healthy volunteers

Inclusion criteria

* DSM-IV -TR Diagnosis axis II: borderline personality disorder; axis I: posttraumatic stress disorder * stable medication * age 18-45 years, gender female * legal competence * sufficient cognitive function * sufficient knowledge of the German or English language

Exclusion criteria

Known severe internal, neurological, musculoskeletal, endocrinological or sleep disorders with organic origin (clinical examination during the screening visit, judged by the investigator) * gravidity (positive ß-HCG test) * continuing and not interruptible exposure to sexual or physical abuse * acute suicidal tendency * positive drug-screening in urine toxicology test

Design outcomes

Primary

Measure	Time frame
Clinician-Administered PTSD Scale (CAPS)	0 - 1 - 6 - 12 - 24 month

Secondary

Measure	Time frame
Borderline symptom checklist 23 (BSL)	0 - 1 - 6 - 12 - 24

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026